Sphincter of Oddi Dysfunction
Conditions
Keywords
Pinaverium Bromide, cholecystectomy, Sphincter of Oddi Dysfunction
Brief summary
Sphincter of Oddi dysfunction (SOD) refers to biliary kinetic abnormality of the sphincter of Oddi (SO), often accompanied by pain, hepatic and pancreatic enzyme elevation, common bile duct (CBD) dilation or onset of pancreatitis. Pain caused by SOD affects the quality of life (QoL).The primary objective of this trial is to evaluate the efficacy of relieving abdominal pain of Pinaverium Bromide in medication therapy for patients with post-cholecystectomy SOD.
Detailed description
1.1 Background (I) 1.1.1 10%\ 50% of the patients who previously underwent cholecystectomy experience recurrent abdominal pain with or without diarrhea, abdominal distention, enzymatic changes, etc., and sphincter of Oddi dysfunction (SOD) accounts for about 13% of such cases; 1.1.2 Sphincter of Oddi dysfunction (SOD): * It refers to biliary kinetic abnormality of the sphincter of Oddi (SO), often accompanied by pain, hepatic and pancreatic enzyme elevation, common bile duct (CBD) dilation or onset of pancreatitis. * Pain caused by SOD affects the quality of life (QoL). 1.1.3 The diagnosis of SOD is still being disputed, and there has been no optimal solution so far. * The diagnosis of SOD is largely based on clinical judgment * The gold standards ERCP and SOM are invasive diagnostic criteria 1.2 Background (II) 1.2.1 If biliary-type abdominal pain after cholecystectomy is considered as SOD, most of the patients are classified as SOD II and SOD III according to Rome III Criteria-modified. Biliary SOD Type I: moderate or severe biliary-type abdominal pain; transient ALT / AST/ALP elevation \> 2ULN; CBD dilation \> 8mm as evidenced by ultrasound or other non-invasive examination Type II: biliary-type abdominal pain; One or two of above items Type III:only biliary-type abdominal pain 1.3 Background (III) 1.3.1 Treatment of SOD is being disputed: currently, the main method is to relax sphincter of Oddi (SO). * Medications: antispasmodic drugs, nitrates, calcium ion antagonists, modulators of gastrointestinal (GI) motility * EST(endoscopic sphincterotomy): postoperative complications and mortality 1.3.2 EST is not well effective in the treatment of SOD type II and type III, which are mostly caused by functional abnormalities -ASGE guideline 2015 points out that EST is not recommended for patients with SOD type III. Endoscopic stents are not recommended, either. 1.3.3 Danshu Capsules: contains the active pharmaceutical ingredient (API) and has the effects of fighting infection, alleviating pain, promoting bile secretion and lifting muscle spasms; literature showed that Danshu Capsules effectively improved the symptoms of biliary disorders, such as pain, nausea and abdominal distension. 1.3.4 Pinaverium Bromide: able to improve the spasms of SO; literature showed that it treated biliary disorders effectively.·10%\ 50% of the patients who previously underwent cholecystectomy experience recurrent abdominal pain with or without diarrhea, abdominal distention, enzymatic changes, etc., and sphincter of Oddi dysfunction (SOD) accounts for about 13% of such cases.
Interventions
DRUGDanshu Capsules
Danshu Capsules (0.9g potid/day) for three months by oral
Pinaverium Bromide (100mg potid/day) for three months by oral
Sponsors
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
* Chief complaint of upper right abdominal pain following LC (within 2 weeks to 6 months) at a hospital visit, but not a pain caused by surgical incision, lasting 3 to 5 minutes each time, without a history of other biliary tract operation * No presence of intestinal obstruction as evidenced by plain abdominal X-ray, with peptic ulcer and duodenal diverticulum ruled out through barium meal examination or gastroscopy * No other obvious abnormalities as evidenced by abdominal ultrasound B and MRCP, except for bile duct dilation * Patients with biliary-type sphincter of Oddi dysfunction (SOD) who are classified as SOD type II (biliary-type abdominal pain accompanied by hepatic enzyme elevation or common bile duct (CBD) dilation) and SOD type III (only biliary-type abdominal pain) according to Geenen-Hogan classification criteria
Exclusion criteria
* Postoperative biliary calculi, benign biliary stenosis, bile duct infection, overlong residual cystic duct (\> 0.5cm), biliary tumors, etc. * Peptic ulcer, duodenal diverticulum * Pancreatitis, pancreatic-type SOD * Adhesive intestinal obstruction * Postoperative irritable bowel syndrome (IBS) * A history of abdominal operation or other surgery * Pregnant and lactating women * Use of other drugs from one week after LC to enrollment, including antispasmodic drugs, analgesics, choleretic agents, calcium ion antagonists and GI motility drugs * A history of allergy to Pinaverium Bromide / Danshu Tablets
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy Evaluation of Reduction in Abdominal Pain Scores，Change From Baseline to 3 Months After Medication | Change From Baseline to 3 Months After Medication | abdominal pain scores (baseline vs. 3 months after treatment) * Abdominal pain score based on main symptom: Degree of pain in point（0 - no pain \[0 point\]；1\ 3 - mild pain \[1 point\]；4\ 6 moderate pain \[2 point\]\]；7\ 10 - severe pain \[3 point\]）、Frequency in times/week (No episodes\[0 point\]；1 time/week\[1 point\]；2 times/week\[2 point\]; 3 times/week\[3 point\])、Duration in days/week(No episodes\[0 point\]；\< 1 day/week\[1 point\]；1-2days/week\[2 points\]；≥ 3days/week\[3 points\]) * The sum of the scores for the above three items is the total score for abdominal pain. * Efficacy evaluation: reduction in abdominal pain score, as compared with the baseline * = 100%: complete remission (CR)；60%\ 99%: significant remission (SR)；30% \ 59%: partial remission (PR)；0% \ 29%: no response (NR) * Treatment response = CR + SR * Treatment response rate = (CR + SR) / the total number of patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the Common Bile Duct (CBD) Diameter Measured by Ultrasound B Once a Month | Once a Month, Four Times Totally (baseline / 4w after treatment / 8w after treatment / 12w after treatment) | Changes in the CBD diameter measured by ultrasound B * Each patient is required to abstain from eating for 12 hours and then takes a measurement of the CBD diameter by ultrasound B the next morning * The measurement takes places once a month, four times totally (baseline / 4w after treatment / 8w after treatment / 12w after treatment) |
| Efficacy of Lowering Liver Enzymes as Assessed by Laboratory Test Once a Month | Once a Month, Four Times Totally (baseline / 4w after treatment / 8w after treatment / 12w after treatment) | * Changes in hepatic enzyme levels (ALT, AST and ALP) * The measurement takes place once a month, four times totally (baseline / 4w after treatment / 8w after treatment / 12w after treatment) |
| Number of Participants With Treatment-Related Diarrhea,Change From Baseline to 3 Months After Medication | From Baseline to 3 Months After Medication | The number of patients presenting the symptoms of diarrhea will be calculated at the time of enrollment (baseline) and 3 months after treatment respectively. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment-Related Adverse Events as Assessed by Researchers or Doctors Through Study Completion | Through Study Completion, An Average of 1 Year | Incidence of adverse events (throughout the treatment) * The type and number of adverse events will be calculated at the baseline and each visit * Inquire about symptoms: rashes, pruritus, acid regurgitation, abdominal distention, diarrhea, etc. * Perform the following examinations at the last visit: blood / urine / stool test, liver / kidney function test, ECG |
Countries
China
Contacts
Primary ContactZhaohui Tang, MD,PhD
Outcome results
None listed